June 1, 2020 / 12:37 PM / a month ago

BRIEF-Revance And Mylan To Advance Development Program For Biosimilar To Botox

June 1 (Reuters) - Mylan NV:

* REVANCE AND MYLAN TO ADVANCE DEVELOPMENT PROGRAM FOR BIOSIMILAR TO BOTOX®

* MYLAN NV - $30 MILLION MILESTONE PAYABLE TO REVANCE FROM MYLAN

* MYLAN NV - COLLABORATION AND LICENSE AGREEMENT ALSO PROVIDES FOR AN ADDITIONAL $70 MILLION IN MILESTONE PAYMENTS

* MYLAN NV - PER AGREEMENT, REVANCE IS ELIGIBLE TO RECEIVE SALES TARGET MILESTONE PAYMENTS AND ROYALTIES IN ALL RELEVANT MARKETS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below